RET and non-small cell lung carcinoma: Non-squamous NSCLC (Non-small-cell lung carcinoma) patients exhibit significant clinical benefits when treated with selpercatinib and pralsetinib, against RET gene fusions, demonstrated by LIBRETTO-001 and ARROW clinical trials [11].